entertainment -WSS

entertainment

author：focus 2025-09-03 03:31:23 - browse：214

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： CRISPR pioneers react to Casgevy, first gene

entertainment

WSS

NIH nominee Bertagnolli will get October confirmation hearing

Weight loss drug costs may need more research, senator suggests

Does good food count as health care? Study aims to find out

Amazon on where the company's health care bets are headed next

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Wikipedia

entertainment

hotspot

Medical leaders decry Supreme Court decision on affirmative action

How generative AI is inspiring dreams of a health data revolution

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Continuity nursing helped my family in our darkest PICU moments

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Apple is now the first public company to be valued at $3 trillion

Weight loss drug costs may need more research, senator suggests

Medical records are filled with copy

Amazon on where the company's health care bets are headed next

leisure time

Does good food count as health care? Study aims to find out

Covid hospitalizations on the rise, Humana says

The 10 drugs up first for Medicare price negotiation

NYU radiologists take on the challenge of expensive MRI machines

Wegovy, Zepbound and weight loss drugs that preserve muscle

ALS advocates say criticism of new drugs misses bigger picture

hotspot

entertainment

entertainment

focus